Dyne Therapeutics
http://www.dyne-tx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dyne Therapeutics
Fulcrum’s Losmapimod Improves Multiple Measures, But Not Primary Endpoint
The ReDUX4 study missed its biomarker-driven primary endpoint, making it unclear if an additional trial will be needed for regulatory submission.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
Finance Watch: VC Mega-Rounds Fund Wide Array, From Respiratory To Rare Diseases
Private Company Edition: China-focused Nuance Pharma led recent venture capital deals with a $181m series D round, RayzeBio closed a $105m series B and SciNeuro launched with $100m plus other notable rounds from Edgewise, Reneo, BioAge and others.
Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies